{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:25Z","timestamp":1792788625768,"version":"4.5.0"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2023Y9451, 2023Y9449"],"award-info":[{"award-number":["2023Y9451, 2023Y9449"]}]},{"name":"Startup Fund for scientific research, Fujian Medical University","award":["2020QH1233"],"award-info":[{"award-number":["2020QH1233"]}],"id":[{"id":"https:\/\/ror.org\/050s6ns64","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J011273"],"award-info":[{"award-number":["2023J011273"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Cancer Hospital High-Level Talent Training Program","award":["2024YNG09"],"award-info":[{"award-number":["2024YNG09"]}]},{"name":"Joint Funds for the National Clinical Key Specialty Construction Program","award":["2021"],"award-info":[{"award-number":["2021"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PIK3CA mutations are among the most common driver mutations in cervical cancer (CC), yet therapeutic strategies targeting PIK3CA mutations are still under investigation. This study aims to evaluate the efficacy and safety of immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs) in patients with PIK3CA-mutated recurrent or metastatic (R\/M) CC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was based on two prospective clinical trials (ChiCTR1900023015 and the CLAP study) and retrospective data from Fujian Cancer Hospital, comparing ICIs combined with TKIs with physician\u2019s-choice Non-ICI\/TKI conventional treatments in PIK3CA-mutated R\/M CC. The primary endpoint was objective response rate (ORR), and secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 55 patients were included, with 27 in the ICIs plus TKIs treatment group and 28 in the Non-ICI\/TKI conventional treatment group. The ORR in the ICIs plus TKIs group was 85.19% (95% CI, 67.52%\u221294.08%), significantly higher than 28.57% (95% CI, 15.25%\u221247.06%) in the Non-ICI\/TKI conventional treatment group (P\u2009&lt;\u20090.001). The PFS in the ICIs plus TKIs group was 21.03 months, significantly longer than 9.13 months in the Non-ICI\/TKI conventional treatment group (HR, 0.49; 95% CI, 0.26\u20130.94, P\u2009=\u20090.033). Although the OS difference was not statistically significant (HR, 0.65; 95% CI, 0.31\u20131.34, P\u2009=\u20090.24), the ICIs plus TKIs group showed superior clinical efficacy. The incidence of hypertension (P\u2009&lt;\u20090.001), rash (P\u2009=\u20090.004), hypothyroidism (P\u2009&lt;\u20090.001), proteinuria (P\u2009=\u20090.010), and palmoplantar erythrodysesthesia syndrome (P\u2009=\u20090.023) was higher in the ICIs plus TKIs group compared to the Non-ICI\/TKI conventional treatment group. The observed adverse events were generally manageable. Although grade \u22653 adverse events occurred, no grade \u22653 immune-related adverse events or treatment-related deaths were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICIs plus TKIs demonstrated significant efficacy in treating PIK3CA-mutated R\/M CC. Although there were some safety concerns, the adverse reactions were manageable, no grade \u22653 immune-related adverse events or treatment-related deaths were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0350571","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:24:21Z","timestamp":1790702661000},"page":"e0350571","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation"],"prefix":"10.1371","volume":"21","author":[{"given":"Lele","family":"Chang","sequence":"first","affiliation":[{"name":"Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, P. R. China"],"department":["Department of Gynecology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Kang","sequence":"additional","affiliation":[{"name":"Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, P. R. China"],"department":["Department of Gynecology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, P. R. China"],"department":["Department of Gynecology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, P. R. China"],"department":["Department of Gynecology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Lan","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Centre","place":["Guangzhou, Guangdong, P. R. China"],"department":["Department of Gynecologic Oncology"]},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine","place":["Guangzhou, Guangdong, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5916-9828","authenticated-orcid":true,"given":"Qin","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital","place":["Fuzhou, Fujian, P. R. China"],"department":["Department of Gynecology"]},{"name":"Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fujian Cancer Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"2","key":"pone.0350571.ref001","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"D Singh","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"3","key":"pone.0350571.ref002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"pone.0350571.ref003","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2019.1646721","article-title":"Pembrolizumab for the treatment of cervical cancer","volume":"19","author":"G Marret","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"36","key":"pone.0350571.ref004","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-Positive cervical cancer: Results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"J-S Frenel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"pone.0350571.ref005","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical Cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"HC Chung","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0350571.ref006","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/modpathol.2016.221","article-title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","volume":"30","author":"EK Enwere","year":"2017","journal-title":"Mod Pathol"},{"issue":"10103","key":"pone.0350571.ref007","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"KS Tewari","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"pone.0350571.ref008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"M Yi","year":"2019","journal-title":"Mol Cancer"},{"issue":"1","key":"pone.0350571.ref009","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","article-title":"Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial","volume":"21","author":"S-Y Wu","year":"2022","journal-title":"Mol Cancer"},{"issue":"9","key":"pone.0350571.ref010","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges","volume":"41","author":"S-J Li","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"16","key":"pone.0350571.ref011","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial","volume":"40","author":"Q Xu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0350571.ref012","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cac2.12547","article-title":"Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study","volume":"44","author":"C Lan","year":"2024","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"pone.0350571.ref013","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/jcm10020220","article-title":"PI3KCA Mutations in Uterine Cervix Carcinoma","volume":"10","author":"IA Voutsadakis","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0350571.ref014","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12920-022-01376-9","article-title":"Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China","volume":"15","author":"J Liu","year":"2022","journal-title":"BMC Med Genomics"},{"issue":"1","key":"pone.0350571.ref015","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41467-018-03867-9","article-title":"Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients","volume":"9","author":"L Chen","year":"2018","journal-title":"Nat Commun"},{"issue":"19","key":"pone.0350571.ref016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910260","article-title":"Growth Factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: Where are we now","volume":"22","author":"C Stefani","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"pone.0350571.ref017","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"I Nederlof","year":"2024","journal-title":"Nat Med"},{"key":"pone.0350571.ref018","doi-asserted-by":"crossref","first-page":"1405521","DOI":"10.3389\/fphar.2024.1405521","article-title":"Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K\/Akt pathway","volume":"15","author":"T Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"pone.0350571.ref019","doi-asserted-by":"crossref","first-page":"101516","DOI":"10.1016\/j.tranon.2022.101516","article-title":"Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K\/AKT\/mTOR pathway","volume":"25","author":"Q Chen","year":"2022","journal-title":"Transl Oncol"},{"issue":"7","key":"pone.0350571.ref020","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.annonc.2021.04.009","article-title":"VP4-2021: EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator\u2019s choice (IC) chemotherapy (chemo) in recurrent\/metastatic (R\/M) cervical carcinoma","volume":"32","author":"KS Tewari","year":"2021","journal-title":"Annals of Oncology"},{"issue":"4","key":"pone.0350571.ref021","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"SP Patel","year":"2015","journal-title":"Mol Cancer Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:24:25Z","timestamp":1790702665000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0350571"}},"subtitle":[],"editor":[{"given":"Evie H.","family":"Carchman","sequence":"first","affiliation":[{"name":"University of Wisconsin","place":["UNITED STATES OF AMERICA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0350571","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}